Medicus Pharma Ltd. has successfully closed its public offering, raising $7.0 million. The company issued 2,260,000 units at a price of $3.10 per unit, with each unit comprising one common share and one warrant to purchase an additional share. The warrants have an exercise price of $3.10 and will expire in five years. Maxim Group LLC served as the lead placement agent, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The proceeds from the offering are intended to fund a Phase 2 clinical trial for basal cell carcinoma treatment using a dissolvable microarray needle skin patch, with potential expansion to other skin disease trials and general corporate purposes. The common shares are traded under the symbol "MDCX" on the Nasdaq Capital Market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。